Dr. Reddy's Laboratories (DRREDDY) Stock Price, Fundamentals & Analysis

What DRREDDY does

Dr. Reddy's Laboratories (DRREDDY) is an integrated pharmaceutical company that operates across North America, Europe, India, Russia, and internationally. It works through three main segments: Global Generics, which manufactures and markets prescription and over-the-counter finished pharmaceutical products as well as biologics; Pharmaceutical Services and Active Ingredients (PSAI), which produces active pharmaceutical ingredients and intermediates and also provides contract research services; and Others, which focuses on developing therapies in oncology and inflammation and on differentiated formulations.

Key numbers explained

• The current price of 1,201 INR reflects the latest trading value on the National Stock Exchange of India stocks.
• The trailing P/E ratio of 30.2 shows how much investors pay per rupee of the last 12 months' earnings; a higher number can signal higher growth expectations or a richer valuation.
• The forward P/E ratio of 20.3 uses expected future earnings, offering a different view of whether the stock looks expensive relative to what is anticipated.
• The dividend yield of 0.67% indicates the annual cash return relative to the share price, based on the declared dividend.
• The ex-dividend date of Jul 10, 2026 is the cutoff: buyers on or after this date do not receive the upcoming dividend.
• The beta of 0.24 suggests the stock has historically moved less than the broader market, with a value below 1 implying lower volatility.
• The return on equity of 8.8 measures how effectively the company generates profit from shareholders' equity.
• The debt-to-equity ratio of 18.6 shows the proportion of debt financing relative to equity, with lower values typically indicating a more conservative capital structure.

What to watch

• Revenue trends: DRREDDY's trailing 12-month revenue of 331.19B INR has declined 5.6% year over year, which can reflect competitive pressure, pricing dynamics, or changes in demand.
• Profitability margins: A 10% profit margin and 4.3% operating margin show how much of each rupee of revenue translates into profit and operating income.
• Earnings cycle: The next earnings report is scheduled for Oct 23, 2026, which often brings price volatility as the market digests results and guidance.
• Peer context: DRREDDY operates alongside companies such as Cipla (CIPLA), Sun Pharma (SUNPHARMA), and Max Healthcare (MAXHEALTH), which can influence sector sentiment.
• Global exposure: As a company with significant operations in North America and Europe, DRREDDY can be affected by currency movements, regulatory changes, and geopolitical developments in those regions.